The findings reveal a slight increase in risk after adenovirus vaccines, which should be taken into account when organizing immunization campaigns and planning future vaccine development.
A new study recently published in The BMJ provides further information on the risk of developing thrombosis with thrombocytopenia syndrome (TTS) after vaccination against the COVID-19 virus.
Based on data from five European nations and the United States, the study reveals a slight increase in the risk of TTS after the first dose of the Oxford-AstraZeneca vaccine, as well as a trend toward an elevated risk after the Janssen/Johnson & Johnson vaccine, as compared to the Pfizer-BioNTech vaccine.
The researchers highlight that this syndrome is very rare, but they add that the risks they have found “should be considered when planning further immunization campaigns and future vaccine development.”
TTS occurs when an individual has both blood clots (thrombosis) and low platelet counts (thrombocytopenia). It is very rare and distinct from other types of clotting conditions such as deep vein thrombosis (DVT) or lung clots (pulmonary embolism).
TTS is now being researched as a rare side effect of adenovirus-based COVID-19 vaccines, which employ a weakened virus to trigger an immune response against coronavirus, although there is no clear evidence on the comparative safety of different types of vaccines.
An international team of researchers set out to compare the risk of TTS or thromboembolic events linked to the usage of adenovirus-based and mRNA-based COVID-19 vaccines in order to address this information gap.
Their findings are based on routinely collected health data for over 10 million adults in France, Germany, the Netherlands, Spain, the UK, and the US who received at least one dose of a COVID-19 vaccine (Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, or Janssen/Johnson & Johnson) from December 2020 to mid-2021.
To minimize possible error, participants were matched by age and sex and a range of other potentially influential factors such as pre-existing conditions and medication use were taken into account.
The researchers then compared rates of thrombosis and of thrombosis with thrombocytopenia between the adenovirus vaccines (Oxford-AstraZeneca or Janssen/Johnson & Johnson) and the mRNA vaccines (Pfizer-BioNTech or Moderna) within 28 days after vaccination.
Overall, 1.3 million first-dose Oxford-AstraZeneca recipients were matched to 2.1 million Pfizer-BioNTech recipients from Germany and the UK.
An additional, 762,517 people receiving Janssen/Johnson & Johnson were matched to 2.8 million receiving Pfizer-BioNTech in Germany, Spain, and the US, and all 628,164 Janssen/Johnson & Johnson recipients from the US were matched to 2.2 million Moderna recipients.
A total of 862 thrombocytopenia events were found in the matched first dose Oxford-AstraZeneca recipients from Germany and the UK, and 520 events after a first dose of Pfizer-BioNTech.
When the data were pooled together, the analysis showed a 30% increased risk of thrombocytopenia after a first dose of Oxford-AstraZeneca compared with Pfizer-BioNTech – an absolute risk difference of 8.21 per 100,000 recipients.
An increase in risk, albeit not statistically significant, of venous thrombosis with thrombocytopenia was observed after a first vaccine dose of Janssen/Johnson & Johnson compared with Pfizer-BioNTech. But the researchers say this finding needs to be replicated in other studies before any firm conclusions can be drawn.
No differential risk of thrombocytopenia was seen after a second dose of Oxford-AstraZeneca compared with a second dose of Pfizer-BioNTech. Similarly, no increased risk of thrombocytopenia was noted after Janssen/Johnson & Johnson compared with a first dose of Pfizer-BioNTech.
This is an observational study, and the researchers acknowledge that the rarity of the condition and incomplete vaccine records may have affected the results. What’s more, they can’t rule out the possibility that some of the observed risk may have been due to other unmeasured (confounding) factors.
However, this was a well-designed study that allowed the comparison of available vaccines with each other, rather than with no vaccination, and the results were consistent after additional analyses, suggesting that they withstand scrutiny.
“To our knowledge, this is the first multinational analysis of the comparative safety of adenovirus-based compared with mRNA-based COVID-19 vaccines,” say the authors.
“Although these events are very rare, absolute numbers of affected patients could become substantial owing to the large numbers of vaccine doses administered worldwide,” they warn.
As such, they suggest that the observed risks after adenovirus-based vaccines “should be considered when planning further immunization campaigns and future vaccine development.”
Reference: “Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US” by Xintong Li, Edward Burn, Talita Duarte-Salles, Can Yin, Christian Reich, Antonella Delmestri, Katia Verhamme, Peter Rijnbeek, Marc A Suchard, Kelly Li, Mees Mosseveld, Luis H John, Miguel-Angel Mayer, Juan-Manuel Ramirez-Anguita, Catherine Cohet, Victoria Strauss and Daniel Prieto-Alhambra, 16 September 2022, The BMJ.
The study was funded by the European Medicines Agency.